INO
Income statement / Annual
Last year (2024), Inovio Pharmaceuticals, Inc.'s total revenue was $217,756.00,
a decrease of 73.83% from the previous year.
In 2024, Inovio Pharmaceuticals, Inc.'s net income was -$107.25 M.
See Inovio Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$217,756.00 |
$832,010.00 |
$10.26 M |
$1.77 M |
$7.41 M |
$4.11 M |
$30.48 M |
$42.22 M |
$35.37 M |
$40.57 M |
| Cost of Revenue |
$0.00
|
$3.50 M
|
$5.50 M
|
$4.73 M
|
$94.25 M
|
$88.02 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$217,756.00
|
-$2.67 M
|
$4.77 M
|
-$2.96 M
|
-$86.83 M
|
-$83.91 M
|
$30.48 M
|
$42.22 M
|
$35.37 M
|
$40.57 M
|
| Gross Profit Ratio |
1
|
-3.21
|
0.46
|
-1.67
|
-11.72
|
-20.41
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$75.62 M
|
$86.68 M
|
$187.65 M
|
$249.24 M
|
$94.25 M
|
$88.02 M
|
$95.26 M
|
$98.57 M
|
$88.71 M
|
$57.79 M
|
| General & Administrative Expenses |
$37.00 B
|
$47.58 M
|
$90.19 M
|
$53.75 M
|
$37.25 M
|
$27.20 M
|
$29.32 M
|
$28.29 M
|
$23.89 M
|
$18.06 M
|
| Selling & Marketing Expenses |
-$36.96 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$37.00 M
|
$47.58 M
|
$90.19 M
|
$53.75 M
|
$37.25 M
|
$27.20 M
|
$29.32 M
|
$28.29 M
|
$23.89 M
|
$18.06 M
|
| Other Expenses |
$0.00
|
$10.51 M
|
-$3.86 M
|
$343,371.00
|
$3.42 M
|
$496,200.00
|
$360,795.00
|
$806,819.00
|
$127,554.00
|
$177,561.00
|
| Operating Expenses |
$112.62 M
|
$144.77 M
|
$277.84 M
|
$302.99 M
|
$131.49 M
|
$115.22 M
|
$124.57 M
|
$126.86 M
|
$112.60 M
|
$75.86 M
|
| Cost And Expenses |
$112.62 M
|
$144.77 M
|
$277.84 M
|
$302.99 M
|
$131.49 M
|
$115.22 M
|
$124.57 M
|
$126.86 M
|
$112.60 M
|
$75.86 M
|
| Interest Income |
$4.77 M
|
$8.13 M
|
$4.78 M
|
$3.36 M
|
$3.31 M
|
$2.61 M
|
$2.26 M
|
$1.61 M
|
$1.40 M
|
$305,071.00
|
| Interest Expense |
$177,833.00
|
$1.22 M
|
$1.25 M
|
$1.94 M
|
$8.70 M
|
$7.95 M
|
$346,086.00
|
$4.56 M
|
$139,249.00
|
$0.00
|
| Depreciation & Amortization |
$3.13 M
|
$3.50 M
|
$5.50 M
|
$4.73 M
|
$4.63 M
|
$5.52 M
|
$5.00 M
|
$3.47 M
|
$3.09 M
|
$1.92 M
|
| EBITDA |
-$103.95 M |
-$130.39 M |
-$270.90 M |
-$296.56 M |
-$149.56 M |
-$107.34 M |
-$89.80 M |
-$84.74 M |
-$74.15 M |
-$33.37 M |
| EBITDA Ratio |
-477.35
|
-156.72
|
-26.17
|
-165.28
|
-10.28
|
-25.68
|
-2.93
|
-1.97
|
-2.13
|
-0.85
|
| Operating Income Ratio |
-516.17
|
-173
|
-26.07
|
-169.72
|
-16.74
|
-27.02
|
-3.09
|
-1.98
|
-2.16
|
-0.85
|
| Total Other Income/Expenses Net |
-$107.14 B
|
$8.82 M
|
-$10.08 M
|
-$2.01 M
|
-$38.81 M
|
-$9.70 M
|
-$706,881.00
|
-$4.56 M
|
$2.50 M
|
$3.08 M
|
| Income Before Tax |
-$107.25 B
|
-$135.12 M
|
-$277.65 M
|
-$303.22 M
|
-$162.89 M
|
-$120.81 M
|
-$94.80 M
|
-$88.21 M
|
-$73.74 M
|
-$31.20 M
|
| Income Before Tax Ratio |
-492542.69
|
-162.4
|
-27.06
|
-170.85
|
-21.98
|
-29.38
|
-3.11
|
-2.09
|
-2.08
|
-0.77
|
| Income Tax Expense |
$0.00
|
$0.00
|
$10.01 M
|
$2.16 M
|
$52.20 M
|
-$257,335.00
|
$2.17 M
|
$1.76 M
|
-$4.62 M
|
-$2.10 M
|
| Net Income |
-$107.25 M
|
-$135.12 M
|
-$287.66 M
|
-$305.38 M
|
-$215.09 M
|
-$120.55 M
|
-$96.97 M
|
-$88.21 M
|
-$73.74 M
|
-$29.19 M
|
| Net Income Ratio |
-492.54
|
-162.4
|
-28.03
|
-172.07
|
-29.02
|
-29.32
|
-3.18
|
-2.09
|
-2.08
|
-0.72
|
| EPS |
-3.95 |
-6.09 |
-14.47 |
-17.55 |
-16.64 |
-14.65 |
-1.05 |
-1.08 |
-1.01 |
-0.43 |
| EPS Diluted |
-3.95 |
-6.09 |
-14.47 |
-17.55 |
-16.64 |
-14.65 |
-1.05 |
-1.08 |
-1.01 |
-0.43 |
| Weighted Average Shares Out |
$27.16 M
|
$22.17 M
|
$19.89 M
|
$17.40 M
|
$12.93 M
|
$8.23 M
|
$92.35 M
|
$81.78 M
|
$73.01 M
|
$68.20 M
|
| Weighted Average Shares Out Diluted |
$27.16 M
|
$22.17 M
|
$19.89 M
|
$17.40 M
|
$12.93 M
|
$8.23 M
|
$92.54 M
|
$81.92 M
|
$73.21 M
|
$68.37 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
